针对肠道沙门菌伤寒血清型与甲型副伤寒血清型的二价结合疫苗在健康印度成人中的安全性与免疫原性:一项1期、随机、阳性对照、双盲试验
该1期双盲随机对照试验纳入60名健康印度成人,按1:1分配接受单剂肌肉注射Sii-PTCV或伤寒结合疫苗Typbar-TCV。Sii-PTCV对伤寒Vi抗原和甲型副伤寒LPS抗原均具免疫原性,且甲型副伤寒抗LPS应答在第181天仍持续;两组均未报告疫苗相关非征集不良事件或严重不良事件。
要点
- Sii-PTCV组和Typbar-TCV组征集性不良事件发生率分别为90%和87%,最常见局部事件为疼痛。
- 第29天抗Vi IgG血清阳转率Sii-PTCV组96.7%、Typbar-TCV组100.0%;抗Vi IgA分别为93.3%和100.0%。
- 第29天抗LPS(甲型副伤寒)血清阳转率Sii-PTCV组100.0%、Typbar-TCV组3.3%;SBA滴度阳转率分别为93.3%和0%。
核心结论
- Sii-PTCV对伤寒和副伤寒抗原均安全且具有免疫原性,提示其有潜力提供针对肠热症的全面保护。
研究设计与样本
- 双盲1期随机阳性对照试验,60名健康印度成人按1:1随机接受单剂肌肉注射Sii-PTCV或Typbar-TCV。
- 安全性评估包括征集性不良事件观察1周、非征集性事件观察1个月、严重不良事件观察6个月。
- 免疫原性在第1个月和第6个月通过ELISA检测抗Vi IgG/IgA和抗LPS IgG,并用血清杀菌试验检测甲型副伤寒功能性抗体。
- 试验在印度临床试验注册中心注册(CTRI/2022/06/043608),已完成。
主要发现
- 60名参与者中57名(95%)为男性、3名(5%)为女性。
- 征集性不良事件在Sii-PTCV组为27/30(90%)、Typbar-TCV组为26/30(87%)。
- 最常见局部征集性事件为疼痛,Sii-PTCV组27名(90%)、Typbar-TCV组23名(77%)。
- 最常见征集性全身事件为肌痛,Sii-PTCV组5名(17%);Typbar-TCV组肌痛4名(13%)、头痛4名(13%)。
- 未报告疫苗相关非征集性不良事件或严重不良事件。
关键数值与推荐
- 第29天抗Vi IgG血清阳转率:Sii-PTCV组96.7%(95%CI 82.8-99.9) vs Typbar-TCV组100.0%(95%CI 88.4-100.0)。
- 第29天抗Vi IgA血清阳转率:Sii-PTCV组93.3%(95%CI 77.9-99.2) vs Typbar-TCV组100.0%(95%CI 88.4-100.0)。
- 第29天抗LPS(副伤寒)血清阳转率:Sii-PTCV组100.0%(95%CI 88.4-100.0) vs Typbar-TCV组3.3%(95%CI 0.1-17.2)。
- 第29天SBA滴度(副伤寒)阳转率:Sii-PTCV组93.3%(95%CI 77.9-99.2) vs Typbar-TCV组0%(95%CI 0.0-11.6)。
- 副伤寒抗LPS免疫应答在第181天仍持续。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Enteric fever caused by Salmonella enterica Typhi and Salmonella Paratyphi A is an important public health problem, especially in low-income and middle-income countries with limited access to safe water and sanitation. We present results from, to our knowledge, the first ever human study of a bivalent paratyphoid A-typhoid conjugate vaccine (Sii-PTCV). METHODS: In this double-blind phase 1 study, 60 healthy Indian adults were randomly assigned (1:1) to receive a single intramuscular dose of either Sii-PTCV or typhoid conjugate vaccine (Typbar-TCV). Safety was assessed by observing solicited adverse events for 1 week, unsolicited events for 1 month, and serious adverse events (SAEs) over 6 months. Immunogenicity at 1 month and 6 months was assessed by measuring anti-capsular polysaccharide antigen Vi (anti-Vi) IgG and IgA against Salmonella Typhi and anti-lipopolysaccharide (LPS) IgG against Salmonella Paratyphi A by ELISA, and functional antibodies using serum bactericidal assay (SBA) against Salmonella Paratyphi A. This study is registered with Clinical Trial Registry-India (CTRI/2022/06/043608) and is completed. FINDINGS: 60 participants were enrolled. Of these 60 participants, 57 (95%) participants were male and three (5%) participants were female. Solicited adverse events were observed in 27 (90%) of 30 participants who received Sii-PTCV and 26 (87%) of 30 participants who received Typbar-TCV. The most common local solicited event was pain in 27 (90%) participants who received Sii-PTCV and in 23 (77%) participants who received Typbar-TCV. The most common solicited systemic event was myalgia in five (17%) participants who received Sii-PTCV, whereas four (13%) participants who received Typbar-TCV had myalgia and four (13%) had headache. No vaccine-related unsolicited adverse events or SAEs were reported. The seroconversion rates on day 29 were 96·7% (95% CI 82·8-99·9) with Sii-PTCV and 100·0% (88·4-100·0) with Typbar-TCV for anti-Vi IgG; 93·3% (77·9-99·2) with Sii-PTCV and 100·0% (88·4-100·0) with Typbar-TCV for anti-Vi IgA; 100·0% (88·4-100·0) with Sii-PTCV and 3·3% (0·1-17·2) with Typbar-TCV for anti-LPS (paratyphoid); and 93·3% (77·9-99·2) with Sii-PTCV and 0% (0·0-11·6) with Typbar-TCV for SBA titres (paratyphoid). Paratyphoid anti-LPS immune responses were sustained at day 181. INTERPRETATION: Sii-PTCV was safe and immunogenic for both typhoid and paratyphoid antigens indicating its potential for providing comprehensive protection against enteric fever. FUNDING: Serum Institute of India.
引用
- Kulkarni PS, Potey AV, Bharati S, et al. The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial. Lancet. 2024. PMID: 38555928. doi:10.1016/S0140-6736(24)00249-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。